Propagation of pathological protein assemblies via a prion-like mechanism has been suggested to drive neurodegenerative diseases, such as Parkinson's and Alzheimer's. Recently, amyotrophic lateral sclerosis (ALS)-linked proteins, such as SOD1, TDP-43 and FUS were shown to follow self-perpetuating seeded aggregation, thereby adding ALS to the group of prion-like disorders. The cell-to-cell spread of these pathological protein assemblies and their pathogenic mechanism is poorly understood. However, as ALS is a non-cell autonomous disease and pathology in glial cells was shown to contribute to motor neuron damage, spreading mechanisms are likely to underlie disease progression via the interplay between affected neurons and their neighboring glial cells.
Prions and prion-like events in neurodegeneration
Neurodegenerative diseases, such as Alzheimer's or Parkinson's disease, are among today's major public health issues. Despite decades of extensive research on the molecular mechanisms driving neurodegeneration, no consensus has yet emerged, thus making it more challenging to develop effective therapies. A common feature of neurodegenerative diseases is the accumulation of misfolded proteins in affected regions of the central nervous system (CNS). The main protein component of these pathological deposits may be unique for each disorder, e.g. ␣-synuclein in Parkinson's disease (PD) or ␤-amyloid in Alzheimer's disease (AD). Moreover, some conditions are characterized by accumulation of more than one misfolded protein. For instance, pathological tau and ␤-amyloid are the primary pathologies in AD, but secondary pathologies, such as TDP-43 (Amador-Ortiz et al., 2007; Uryu et al., 2008) and ␣-synuclein (Hamilton, 2000; Higashi et al., 2007) , also occur in ∼30-40% of AD patients. In addition, one type of aggregated protein may be observed in multiple disorders, such as TDP-43, which is found abundantly in the pathogenic inclusions of patients with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) (Arai et al., 2006; Neumann et al., 2006) , but also many other diseases, including a fraction of AD and PD cases (Banks et al., 2008; Lagier-Tourenne et al., 2010; Walker et al., 2014) .
In the recent years, increasing evidence supports a common mechanism driving neurodegeneration in many clinically diverse conditions. This pathogenic mechanism involves formation of aberrant protein aggregates, which is propagated in a self-templating manner (Fig. 1A) . Indeed, misfolded protein assemblies have been shown to act as seeds of aggregation that can sequester their native isoforms and convert them into pathological molecules, thereby growing in size. Subsequent fragmentation of the aggregates and repetition of the cycle leads to amplification of the pathological state within one cell, as well as through the nervous system via the release of seeds to the extracellular space, uptake by the neighboring cells and repetition of the propagation cycle.
This mechanism, resembles the replication of infectious prions, and is therefore often termed "prion-like" (Goedert et al., 2010; Guo and Lee, 2014; Jucker and Walker, 2013; Cleveland, 2011, 2012) . Prion diseases, also called transmissible spongiform encephalopathies, are neurological disorders, which unlike any other human neurodegenerative disease, can be transmitted between individuals. The infectious agent is the prion, which consists only of misfolded pathogenic protein (Prusiner, 1982) . Besides infectious etiology, prion diseases, like other neurodegenerative disorders, can have sporadic or familial origin. In the latter, heritable mutations occur in the PRNP gene encoding the cellular prion protein. The disease mechanism is based on the conversion of the normal cellular isoform of the prion protein, PrP C , to a misfolded highly aggregative form, PrP Sc , triggering a widespread misfolding and fibril formation across the nervous system in a 
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Fig. 1. Prion-like propagation mechanisms. (A)
In the classical view of prion-like amplification of pathological protein conformation, the misfolded protein interacts with its native counterpart and converts it into a pathological molecule. This aberrant aggregate elongates by recruitment and conversion of further native protein, which produces a highly ordered seed of aggregation. The latter eventually fragments, resulting in multiple seeds, which induce next cycles of seeded nucleation and amplify the pathological protein aggregation and disease phenotype. (B) For RNA-binding proteins with prion-like domains, such as TDP-43 and FUS, aggregate nucleation may be initiated within the stress granules, which are highly dynamic and strictly regulated protein-RNA complexes forming in cellular stress conditions. The formation of stress granules involves RNA-binding and conformational change and results in the increase of local protein concentration. In disease, potentially as a consequence of yet uncharacterized chronic cellular stress conditions, the highly concentrated RNA-binding proteins in stress granules may transform into pre-inclusions and eventually convert into irreversible protein aggregates.
self-perpetuating manner (Aguzzi, 2009; Aguzzi and Polymenidou, 2004; Aguzzi and Rajendran, 2009 ). Indeed, mice lacking the prion protein are completely resistant to prion disease (Bueler et al., 1993) . The pathology of prion diseases is characterized by protein aggregation, neuronal loss, gliosis and spongiform degeneration (Aguzzi and Polymenidou, 2004) . Moreover, the misfolded prion protein was shown to acquire several different structural conformations, referred to as strains, which lead to development of various disease phenotypes with distinct histopathological signatures, incubation periods and severity of disease progression (Aguzzi et al., 2007) . The recognition that pathological aggregates of ␤-amyloid, tau, ␣-synuclein and others behave in a prion-like manner has major implications for disease initiation and progression (Goedert et al., 2010; Guo and Lee, 2014; Jucker and Walker, 2013; Cleveland, 2011, 2012) . Indeed, it has been suggested that most neurodegenerative disorders spread in a spatiotemporal fashion through mechanisms involving the seeded aggregation of pathogenic proteins, which trigger neurotoxicity and eventually neuronal cell death (Aguzzi, 2009; Aguzzi and Rajendran, 2009; Goedert et al., 2010; Cleveland, 2011, 2012) . There is substantial evidence supporting this hypothesis, as amyloid-␤ (Meyer-Luehmann et al., 2006) , tau (Clavaguera et al., 2009; Liu et al., 2012; Nonaka et al., 2010) , and ␣-synuclein (Luk et al., 2012; Masuda-Suzukake et al., 2013; Nonaka et al., 2010; Volpicelli-Daley et al., 2011) aggregates were able to induce native protein misfolding and cell-to-cell transmission, both in vitro and in vivo.
Terminology
While recent evidence indicates that the molecular mechanisms underlying the replication of prions is fundamentally the same with the mechanisms propagating pathological aggregates in other neurodegenerative diseases, there is one substantial difference. There is currently no evidence that any other human neurological disorder, besides prion diseases, can be transmitted from one individual to another . Therefore a specific terminology is needed to distinguish them from prion diseases. Since the scientific community has not fully settled on this terminology, we define our interpretation of the most commonly used terms below.
The self-perpetuating propagation of misfolding and aggregation, resembling that of prion amplification, is referred to as 'prion-like' mechanism. The term 'seeding' is used to describe the templated aggregation and conversion of a large amount of natively folded protein into pathological conformation, via the introduction of minute amounts of preformed aggregates. Although, seeding is mostly referred to in vitro assays on purified proteins, it could be extended to mean the same type of molecular events occurring within a cell. 'Nucleation' refers to the initial phase of the seeding process, namely formation of the seed of aggregation. The propagation of aggregates within one organism, via cellular connections, exo/endocytosis mechanisms and possibly other, yet unclarified events, is often called 'cell-to-cell spreading'. Lastly, the term 'prionoid' has been coined to differentiate the pathological proteins causative for prion-like diseases from the bona fide infectious prion (Aguzzi, 2009) .
Within the recent years exciting reports emerged, suggesting that ALS-linked pathological proteins are indeed prionoids, as they have the potential to seed and propagate their pathological conformation through recruitment of native proteins. Consequently, one major focus of ALS research today is the investigation of the role of seeded aggregation mechanisms in ALS pathogenesis.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is an adult-onset neurodegenerative disorder, which is characterized by rapidly progressive weakness and muscular wasting, leading to paralysis and death due to respiratory failure within 1-5 years from disease onset (Ilieva et al., 2009; . ALS is the most common motor neuron disease that affects more than 1 in 100,000 individuals each year. The major risk factor of ALS is age, as the disease most commonly occurs between 40 and 60 years. However, there are other environmental factors that increase the risk of developing ALS, such as lifetime of intensive physical activity (Kiernan et al., 2011; Scarmeas et al., 2002; Veldink et al., 2005) , as in the case of professional football players (Chio et al., 2005) or members of the military (Weisskopf et al., 2005) .
The majority of ALS cases (90%) presents spontaneous onset without any evidence of inheritance, and is referred to as sporadic ALS (sALS). The remaining 10%, classified as familial ALS (fALS), shows an apparent hereditary contribution and is linked to dominant inheritance of mutations in several ALS-linked genes. Mutations in the gene encoding copper/zinc superoxide dismutase 1 (SOD1) were the first identified genetic causes of ALS, which account for 20% of fALS (Rosen et al., 1993) . Subsequent generation of transgenic mice and rats expressing ALS-causing SOD1 mutants (Bruijn et al., 1998; Gurney et al., 1994; Wong et al., 1995) , which remain the most faithful animal models for ALS, has focused attention to research aiming at deciphering the molecular mechanisms in SOD1-linked ALS.
A shift of interest occurred many years later, with the recognition that TAR DNA-binding protein of 43 kDa (TDP-43) is the major component of ubiquitin-positive, cytoplasmic inclusions found abundantly in patients with sporadic ALS (Arai et al., 2006; Neumann et al., 2006) . This discovery was rapidly followed by the identification that mutations in the TARDBP gene cause ALS (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008) . A year later, mutations in another RNA/DNA-binding protein, referred to as fused in sarcoma (FUS) or translocated in liposarcoma (TLS) (Kwiatkowski et al., 2009; Vance et al., 2009 ) were shown to cause rare cases of familial ALS. Most recently, large expansions in an intronic hexanucleotide repeat region of an uncharacterized gene, called C9ORF72, were identified in ∼10% of all ALS cases, rendering it the most common genetic cause of the disease (Renton et al., 2011; DeJesus-Hernandez et al., 2011) . Furthermore, mutations in many other genes were shown to cause familial forms of ALS (reviewed in Rademakers and van Blitterswijk, 2013; Renton et al., 2014) , which even though are evidently rare, may contribute to our understanding of disease mechanisms, especially as they point toward common pathways with other ALS-causing genes. Additionally, ALS was considered for many years to be a cell-autonomous disease that leads to a selective degeneration and death of upper and lower motor neurons. However, it is now established that other cell types, mainly the neighboring glial cells, significantly contribute to the progression of ALS (reviewed in Ilieva et al., 2009) . These discoveries of the past ∼10 years suggest that ALS is a heterogeneous and multifactorial disease, in which neuronal cell death can result from many different upstream triggers that potentially converge to common downstream mechanisms.
In this review we will focus on the genes that define the majority of ALS, namely SOD1, TARDBP, FUS and C9ORF72. We will discuss the evidence that protein products originating from these genes have the potential to form pathological protein assemblies that may amplify and spread their pathological conformation throughout the nervous system in a prion-like manner.
Superoxide dismutase 1 (SOD1)
SOD1 was the first -and for a long time the only -protein found to be involved in ALS pathogenesis (Rosen et al., 1993) and till now more than 170 ALS-linked mutations were identified in the SOD1 gene. These mutations span the entire protein sequence suggesting that any single nucleotide substitution is sufficient to trigger pathological changes in protein conformation. The deposition of misfolded SOD1 caused by SOD1 mutations account for approximately 20% of fALS.
SOD1 is a 153 amino acid enzymatic protein that plays a role in scavenging free superoxide radicals in the body. Under native conditions, SOD1 forms a stable homodimer ( Fig. 2A ) that is primarily diffused in the cytoplasm (Crapo et al., 1992) , but was also found to localize within the mitochondrial intermembrane space (Higgins et al., 2002; Okado-Matsumoto and Fridovich, 2001) . ALS-causing mutations lead to instability of the homodimer and consequently trigger misfolding of SOD1 and its accumulation within cells (Fig. 2B ). Multiple toxic properties acquired by such SOD1 deposits, rather than disruption of normal enzymatic function of the protein, mediate neurotoxic pathways leading to neurodegeneration and neural cell death in ALS (Ilieva et al., 2009 ). For instance, pathogenic SOD1 may cause postsynaptic neurotoxicity due to misregulation of synaptic glutamate clearance, leading to accumulation of glutamate and subsequent glutamate-induced excitotoxicity (Bruijn et al., 1997; Rothstein et al., 1995) . Aggregated SOD1 has also been shown to induce ER stress through its concentration in the ER lumen or association with the ER membranes and interference in the ER-associated degradation (ERAD), a process important for elimination of misfolded proteins (Kikuchi et al., 2006; Nishitoh et al., 2008) . Additionally, mutant SOD1 has been suggested to impair normal proteasome function by inhibition of the degradation pathways responsible for removal of abnormal proteins from the cell (Bendotti et al., 2012) . Other reported mechanisms involve mitochondrial damage, based on observation of an aberrant morphology and dysfunction of mitochondria caused by mutant SOD1 deposition on the mitochondrial membranes (Igoudjil et al., 2011; Vande Velde et al., 2008) . Furthermore, pathogenic SOD1 may be secreted from affected cells and therefore induce extracellular toxicity, modulate activation of the neighboring microglia and consequently increase the rate of neuronal cell death (Ilieva et al., 2009) .
While all mechanisms mentioned above are likely to contribute to the pathogenesis of SOD1-linked ALS, the challenge now is to identify which one(s) are indeed triggering the disease and which are merely consequences of motor neuron death.
TAR DNA-binding protein of 43 kDa (TDP-43)
The identification of TDP-43 as the major component of ubiquitin-positive, cytoplasmic inclusions in patients with ALS (Arai et al., 2006; Neumann et al., 2006 ) was a turning point in ALS research. Soon after this discovery, several dominant mutations in the TARDBP gene, which encodes TDP-43, were found to be causative for familial ALS (∼4-5% of cases) and were also identified in rare (∼1%) sporadic cases (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008) . These findings strongly suggest that pathological forms of TDP-43 could directly induce neurotoxic pathways leading to neurodegeneration. TDP-43 pathogenic aggregates are now recognized as a characteristic feature of the majority (∼97%) of ALS patients. Interestingly, these inclusions are absent in familial ALS cases with SOD1 mutations (Mackenzie et al., 2007) , which implies that different upstream mechanisms drive neurodegeneration in TDP-43 and SOD1 proteinopathies.
TDP-43 is a 414 amino acid protein that is highly conserved and belongs to the ribonucleoprotein family. TDP-43 contains two RNA recognition motifs (RRM1 and RRM2) that are evolutionarily conserved and are involved in nucleic acid binding ( Fig. 2A) . The C-terminal domain, which was shown to be highly aggregation prone, contains a glycine-rich region important for protein interactions. TDP-43 also contains a nuclear localization signal (NLS) and a nuclear export signal (NES), which allow the shuttling of TDP-43 between the nucleus and the cytoplasm. While in healthy cells, TDP-43 localizes predominantly to the nucleus, in affected neurons and glial cells, it mislocalizes to the cytoplasm, where it forms pathogenic inclusions ( Fig. 2B ). This protein redistribution and cytoplasmic aggregation prevents TDP-43 from returning to the nucleus, leading to its nuclear clearing (Arai et al., 2006; Igaz et al., 2008; Neumann et al., 2006; Van Deerlin et al., 2008) . Moreover, disease-associated TDP-43 presents a certain biochemical signature characterized by polyubiquitination, hyperphosphorylation and proteolytic cleavage (Arai et al., 2006; Neumann et al., 2006) . The latter gives rise to highly aggregative C-terminal fragments that are deposited in the cytoplasm along with the full-length (Auclair et al., 2013) ; ribbon representation of RNA-binding domain of TDP-43 in complex with RNA molecule (Lukavsky et al., 2013) . Ribbon representation of RNA-binding domain of FUS . The structures of FUS protein and C9ORF72 dipeptide-repeat proteins have not been yet resolved. (B) Pathology: SOD1 cytoplasmic inclusions in motor neurons of the spinal cord from ALS patient with hSOD1 A4V mutation (Kerman et al., 2010) ; ubiquitin-positive cytoplasmic inclusions of pathogenic TDP-43 in the spinal cord of an ALS patient (Arai et al., 2006) ; FUS cytoplasmic inclusions with granular morphology in lower motor neurons of fALS patient with FUS A521C mutation ; cytoplasmic inclusions of dipeptide repeat proteins from the characteristic TDP-43-negative inclusions in C9ORF72 patients (Mori et al., 2013) . (C) Seeded aggregation in vitro: SOD1: spontaneous and self-seeded aggregation reactions (in absence or presence of preformed SOD1 fibrils, respectively) of wild type SOD1 protein. Addition of SOD1 seeds significantly increased aggregation kinetics (Chia et al., 2010) ; TDP-43: seeded aggregation of refolded C-terminal fragment of TDP-43 (TDP-43-Cterm) using preformed TDP-43-Cterm aggregates as seeds. Without addition of seeds, TDP-43 did not form aggregates (Furukawa et al., 2011) ; FUS: seeded aggregation reaction of wild type FUS protein with and without addition of preformed mutant FUS aggregates as seeds. In the absence of seeds, the wild type FUS did not form aggregates (Nomura et al., 2014) . (D) Seeded aggregation in cell culture: SOD1: transiently transfected cells expressing mutant SOD1 tagged with GFP were inoculated with exogenous fluorescently modified mutant SOD1 aggregates. The endogenously expressed mutant SOD1 was evenly distributed in untreated cells. In contrast, upon treatment with exogenous SOD1 aggregates, it formed inclusions that co-localized with the seeds (Münch et al., 2011) ; TDP-43: transiently transfected cells expressing a truncated C-terminal form of TDP-43 or full length TDP-43, both HA tagged, were transduced with fluorescently modified exogenous aggregates, composed of a C-terminal form of TDP-43. Intracellular inclusions of endogenous proteins co-localized with aggregates used as seeds (Furukawa et al., 2011). TDP-43 (Igaz et al., 2008; Neumann, 2009 ). Importantly, the majority of ALS-linked missense mutations is localized in the C-terminal glycine-rich domain Ling et al., 2013) and was shown to significantly increase the aggregation propensity of TDP-43 (Guo et al., 2011; Johnson et al., 2009 ).
Fused in sarcoma (FUS) or translocated in liposarcoma (TLS)
Soon after the identification of TDP-43, ALS-causing mutations were found in another DNA/RNA-binding protein, named FUS, also referred to as TLS (Kwiatkowski et al., 2009; Vance et al., 2009) . Missense mutations in the FUS gene account for approximately 4% of fALS cases and rare sporadic cases (Kwiatkowski et al., 2009; Vance et al., 2009) , some of which present with juvenile onset and unusually rapid disease progression (Baumer et al., 2010; Yan et al., 2010; Zou et al., 2013) .
FUS is a 526 amino acid long ribonucleoprotein that binds nucleic acids through its C-terminal part, which comprises an RNA recognition motif (RRM), two glycine-arginine-rich motifs and a zinc finger domain. The N-terminal part, which shows high aggregation propensity, contains a glycine-rich region and a domain enriched in glutamine, glycine, serine, and tyrosine residues . FUS contains NLS and NES sequences, which allow its shuttling between the nucleus and the cytoplasm, suggesting that FUS is involved in RNA metabolism pathways that take place in both cellular compartments (Lagier-Tourenne et al., 2010).
Nevertheless, FUS predominantly localizes to the nucleus of healthy cells, whereas in ALS patients with FUS mutations, pathological protein is redistributed to the cytoplasm of affected cells where it accumulates and aggregates (Fig. 2B) . This mislocalization leads to partial loss of nuclear protein Vance et al., 2009) , similarly to TDP-43 pathology. The majority of FUS mutations are clustered in the NLS sequence, which is embedded within the highly conserved extreme C-terminus Ling et al., 2013) . These mutations were shown to enhance cytoplasmic localization of FUS (Dormann et al., 2010; Ito et al., 2011) , rather than its aggregation propensity (Dormann et al., 2010; Sun et al., 2011) . Strikingly, while the pathogenic FUS aggregates are immunoreactive for p62 and ubiquitin, in contrast to the characteristic pathological signature of most ALS cases, FUS inclusions are TDP-43-negative (Suzuki et al., 2010; Tateishi et al., 2010; Vance et al., 2009 ).
TDP-43 and FUS pathogenic mechanisms
The mutual exclusion of TDP-43 and FUS pathology, in combination with the high structural and functional similarity of the two proteins, suggest that they mediate independent initiation steps, which could eventually lead to activation of common downstream pathways. The latter may result either from loss of their normal nuclear function, because of protein redistribution and aggregation in the cytoplasm, or from gain of toxic function, due to deposition of the misfolded protein assemblies in the cytoplasm. It is important to note that these two mechanisms are not mutually exclusive and likely cause motor neuron degeneration in conjunction (LagierTourenne et al., 2010; Ling et al., 2013; .
The loss of normal TDP-43 or FUS function is most likely linked to the central role that each protein plays in RNA maintenance and processing. Indeed, both proteins are involved in multiple steps of RNA metabolism, from transcription regulation and pre-mRNA maturation, to mRNA transport, translation and microRNA biogenesis . Novel approaches that combine cross-linking, immunoprecipitation with high-throughput sequencing have shown that TDP-43 Tollervey et al., 2011) and FUS (LagierTourenne et al., 2012; Rogelj et al., 2012) bind an overwhelming number of RNA targets in the adult mouse and human brain, presenting an extremely broad spectrum of possible aberrant TDP-43 and FUS functions. While it is difficult to specify which of them are essential to trigger neurodegeneration in ALS, given their apparent mutually exclusive role in disease, an attractive approach is the definition of common TDP-43 and FUS RNA targets. Indeed, although TDP-43 and FUS bind a distinct spectrum of RNAs, they both showed high preference for mRNAs derived from genes with exceptionally long introns . Importantly, 45 common TDP-43 and FUS RNA targets, the majority of which are important for normal neuronal function, are significantly downregulated upon depletion of either TDP-43 or FUS in the adult mouse brain and in cultured human neurons . High abundance in the brain of these long-intronic genes (Ameur et al., 2011; , which are bound with very high affinity by both TDP-43 and FUS, presents a possible explanation of why neurons are mostly susceptible to ALS pathogenic processes. Moreover, a recent study showed that ALS-linked mutations impair the transport of TDP-43-containing RNA granules to distal neuronal compartments (Alami et al., 2014) , suggesting another important role of TDP-43, whose disruption in ALS may lead to neuronal malfunction. It remains to be seen whether FUS plays a similar role in neuronal RNA transport and whether this process is affected in disease. Furthermore, FUS and TDP-43 proteins were found to physiologically interact, and ALS-linked mutations in TARDBP gene seem to enhance this interaction (Ling et al., 2010) . This adds yet another indication for convergence of TDP-43 and FUS-mediated pathogenic pathways.
The study of the direct toxicity of TDP-43 and FUS aggregates has been compromised by the unfortunate lack of cellular and animal models that faithfully recapitulate protein aggregation (Laferriere and Polymenidou, 2015) . Consequently, it remains unclear whether TDP-43 and FUS cytoplasmic aggregates are a primary cause of ALS, an inert byproduct of the disease process, or even the result of a protective cellular response to neurodegeneration. Elegant studies with sophisticated imaging technologies in cultured neurons suggested that increased cytoplasmic, but not aggregated TDP-43 is neurotoxic (Barmada et al., 2010 (Barmada et al., , 2014 . Moreover, this toxicity is enhanced by an ALS-linked mutation (Barmada et al., 2010) and can be ameliorated by TDP-43 clearance via activation of autophagy (Barmada et al., 2014) . These findings, in combination with the prion-like amplification of pathology described below, suggest that, at least a part of the TDP-43 and FUS protein aggregates are likely to be -directly or indirectly -neurotoxic. Therefore, further studies are desperately needed to better characterize the diseaseassociated protein assemblies, as well as to define their potential neurotoxic properties.
Chromosome 9 open reading frame 72 (C9ORF72)
One of the most exciting discoveries in the ALS field was the identification of intronic hexanucleotide repeat expansions in the C9ORF72 gene of ALS patients, which is now recognized as the most frequent genetic cause of ALS accounting for ∼40% of fALS and ∼7% of sALS cases (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Majounie et al., 2012; Renton et al., 2011) . In healthy individuals, the repeat length is shorter than 25-30 units, whereas in C9ORF72 ALS patients, the number of repeats can expand to 700 repeats or more, with some patients carrying extremely long repeats of >3000 units (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; van Blitterswijk et al., 2013) . C9ORF72-linked ALS cases show a complex pathological signature, which besides the typical TDP-43 aggregation, is characterized by p62-positive and TDP-43-negative ubiquitinated inclusions in the cerebellar and hippocampal regions (Al-Sarraj et al., 2011; DeJesus-Hernandez et al., 2011; Troakes et al., 2012) , which are usually free of pathology in non-C9ORF72 ALS (Geser et al., 2008 (Geser et al., , 2009 ). These inclusions contain one of five different aggregating dipeptide-repeat (DPR) proteins, namely poly-(Gly-Ala), poly-(Gly-Pro), poly-(Gly-Arg), poly-(Pro-Arg) and poly-(Pro-Ala) Mori et al., 2013; Zu et al., 2013) . These DPR proteins are generated by an unconventional type of translation, called repeat-associated non-ATG (RAN) translation (Zu et al., 2011) , which operates on sense Mori et al., 2013) and antisense (Zu et al., 2013) transcripts originating from the hexanucleotide repeat RNA. Moreover, hexanucleotide repeats themselves were also found to accumulate in nuclear RNA foci in neurons (DeJesus-Hernandez et al., 2011) and glial cells (Lagier-Tourenne et al., 2013) of C9ORF72 ALS patients (Fig. 1B) .
Repeat expansions have been previously reported to disrupt RNA metabolism in other neurodegenerative diseases (Ranum and Cooper, 2006) . Therefore, C9ORF72, additionally to FUS and TDP-43, has drawn even more attention to research aiming to understand the role of potential RNA misregulation in ALS (Donnelly et al., 2013; . The C9ORF72 gene itself is poorly characterized and the physiological role of encoded protein remains to be determined. However, ALS-associated hexanucleotide repeat expansions result in reduced levels of C9ORF72 RNA (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012) , either due to the inactivation of the repeat-containing allele via promoter hypermethylation (Xi et al., 2013) , or transcriptional abortion of repeat RNAs (Haeusler et al., 2014) . The lower C9ORF72 RNA and the resulting reduced protein levels may be insufficient for its normal function, a phenomenon known as haploinsufficiency. Moreover, the RNA hexanucleotide foci may be directly toxic by acquiring complex secondary structures, such as G-quadruplexes and hairpins and by binding essential proteins, such as nucleolin, whose sequestration leads to nucleolar stress and other downstream defects (Haeusler et al., 2014) . Lastly, while the role of DPRs in the pathogenesis of C9ORF72 ALS remains unclear, recent studies have shown that DPRs can confer toxicity in cultured cells, via interfering with RNA biogenesis (Kwon et al., 2014) and protein trafficking (May et al., 2014) .
Self-propagation of protein misfolding and aggregation
An increasing number of reports suggest that the main protein products defining ALS pathology described above, can behave in a prion-like manner, both in vitro and in cell culture (Fig. 2) . While most of the proteins that misfold and accumulate in neurodegeneration, including TDP-43 and FUS, are intrinsically aggregation-prone, SOD1 is an exception to this rule. Wild type SOD1 is structurally one of the most stable proteins, which may explain why no bona fide protein inclusions of wild type SOD1 have been, unequivocally, described in human patients (Brotherton et al., 2012; Kerman et al., 2010) , despite claims of abnormal, cytoplasmic SOD1 immunoreactivity in a subset of sporadic ALS patients (Bosco et al., 2010) . Nevertheless, pure, recombinant, wild type SOD1 can form fibrils spontaneously, while conditions that disrupt its stable dimer, such as reducing agents or high temperature, accelerate the aggregation reaction (Chia et al., 2010; Münch et al., 2011) . Also, similarly to TDP-43 (Guo et al., 2011; Johnson et al., 2009) , ALS-linked mutations in SOD1 promote aggregation (Chia et al., 2010; Prudencio et al., 2009 ). In contrast, most of the ALSlinked FUS mutations are localized in the NLS and do not influence aggregation per se, but rather promote redistribution of FUS to the cytoplasm (Dormann et al., 2010; Ito et al., 2011; Sun et al., 2011) , which consequently may initiate its aggregate nucleation. The high propensity of TDP-43 and FUS to aggregate is linked to the presence of a glycine-rich domain in both proteins, namely in the N-terminal part of FUS (amino acids 1-239) and the C-terminal part of TDP-43 (amino acids 274-414). Such domains, which are frequently found in RNA-binding proteins, have similar amino acid composition with yeast prion proteins and are therefore also called "prion-like" (Cushman et al., 2010) , or low complexity domains (Kato et al., 2012) , and can acquire disordered structures upon protein folding .
In vitro studies demonstrated that even small amounts of aggregated SOD1 (Chia et al., 2010) , TDP-43 (Furukawa et al., 2011) or FUS (Nomura et al., 2014) were able to induce misfolding and aggregation of their corresponding natively folded protein, implicating template-dependent propagation (Fig. 1C) . The prion-like domains of TDP-43 (Furukawa et al., 2011; Guo et al., 2011; Johnson et al., 2009; Nonaka et al., 2009 ) and FUS apparently mediate protein aggregation and contribute to their seeding ability. Indeed, increased expression of the TDP-43 glycine-rich domain, induced protein accumulation and cell toxicity (Furukawa et al., 2011; Guo et al., 2011; Johnson et al., 2009; Liu-Yesucevitz et al., 2010; Pesiridis et al., 2011; Zhang et al., 2009 ). On the contrary, deletion of the TDP-43 (Furukawa et al., 2011; Johnson et al., 2009 ), or FUS (Sun et al., 2011 prion-like domains prevented aggregate formation, which indicates that these domains are required for efficient seeding. Importantly, the prion-like domain of TDP-43 is the main protein product forming the cytoplasmic inclusions in ALS patients (Igaz et al., 2008; Neumann, 2009) , and the majority of ALSlinked mutations are localized mainly within this domain. While the above observations have focused attention to the C-terminal part of TDP-43, two recent studies highlight the significance of an N-terminal segment for its function and aggregation. Indeed, the N-terminal part of TDP-43 was reported to regulate proper protein folding and function such as splicing regulation, but is also necessary for TDP-43 aggregation . This unexpected function is mediated by its unusual structural switch from a folded, ubiquitin-like domain upon binding to single stranded DNA and in low protein concentrations, to an unfolded and aggregation-prone structure when protein concentrations are increased (Qin et al., 2014) .
FUS is characterized by even higher aggregation propensity compared to SOD1 or TDP-43, as it was shown to spontaneously aggregate into fibrils in a cell-free system within minutes . Aggregates reconstituted in vitro from recombinant wild type or mutant SOD1 (Furukawa et al., 2013; Münch et al., 2011) and TDP-43 (Furukawa et al., 2011 ) triggered aggregation of endogenously expressed protein in cell culture (Fig. 2D) . While this has not yet been shown for FUS, it was recently reported that coexpression of mutant and wild type FUS induces aggregation of the otherwise soluble wild type FUS, albeit, this aggregation seems to be confined in the nucleus (Nomura et al., 2014) , in contrast to what is typically seen in ALS patients (Fig. 2B) . Recently, the insoluble TDP-43 aggregates derived from brain homogenates of ALS patients were shown to seed protein misfolding and accumulation in TDP-43 transfected cultured cells . Importantly, the induced TDP-43 and SOD1 (Grad et al., 2011; Münch et al., 2011) aggregates persisted within cells when the original pathogenic seed was no longer present. Therefore, the newly induced aggregates can act as new misfolding templates and exhibit properties consistent with prion-like propagation.
Although several laboratories are currently studying these prion-like phenomena in animals, until now, the seeding of ALSlinked proteins has not been shown conclusively in vivo. However, the first implication for the in vivo transmissibility of SOD1 pathology was recently reported (Ayers et al., 2014) . In this study, genetically vulnerable mice, expressing G85R-SOD1:YFP fusion protein, were intraspinally injected with homogenates from terminally sick, paralyzed mutant mice. The injected mice developed motor neuron disease and exhibited a widespread redistribution of endogenous SOD1 to protein inclusions, found abundantly throughout the spinal cord, brainstem and thalamus. While these data strongly support the prion-like propagation of misfolded SOD1 in vivo, the lack of transmissibility to mice overexpressing wildtype human SOD1 suggests that the process is extremely inefficient and depends on the loosening of the stable SOD1 dimeric structure by the presence of the YFP tag.
Further supporting seeded aggregation and spread of misfolded SOD1 in vivo, transgenic mutant human SOD1-expressing mice presented accelerated disease progression and shorter lifespan upon co-expression of wild type human SOD1 (hSOD1 WT ) (Deng et al., 2006) . Surprisingly, double-transgenic mice co-expressing hSOD1 WT with hSOD1 A4V , the most aggressive SOD1 mutant in humans, which does not cause disease in mice (Gurney et al., 1994) , resulted in ALS-like phenotype (Deng et al., 2006) . The conversion of unaffected to pathogenic phenotype may be explained by prionlike misfolding of human wild-type SOD1 by the A4V mutant in the double-transgenic mouse. Indeed, disease in these mutant/wild type co-expressing mice is accompanied by high levels of insoluble wild type SOD1, suggesting that misfolded, mutant SOD1 assemblies can recruit and convert wild type SOD1 to an aberrant isoform, in a template-directed manner. Interestingly, transgenic mice greatly overexpressing hSOD1 WT were also shown to exhibit SOD1 aggregation, neurotoxicity and shortened lifespan (Graffmo et al., 2013) . These data suggest that not only mutant, but also wild type human SOD1, may be involved in development of ALS in humans (Deng et al., 2006; Graffmo et al., 2013) . It is also important to note, that moderate overexpression of wild type human TDP-43 (hTDP-43 WT ) in transgenic mice, also caused an ALS-like phenotype, characterized by TDP-43 proteolytic cleavage, deposition of cytoplasmic inclusions immunopositive for phosphorylated TDP-43, axonal degeneration and early lethality (Xu et al., 2010) . These mice, however, do not fully recapitulate human ALS, as they do not develop fatal paralysis or protein aggregation in their nervous system. Taken together, the above studies indicate that prion-like seeding of misfolded SOD1, TDP-43 and FUS proteins, may drive the pathogenic pathways leading to neurotoxicity and neuronal cell death in ALS .
RNA binding and autoregulation promote prion-like propagation and toxicity
The mechanisms driving onset of ALS, as well as most of the other neurodegenerative disorders, remain unknown. Factors that facilitate protein aggregation in subcellular compartments, such as mutations that increase the aggregation propensity of the protein, are potential culprits. In the absence of identified genetic cause, attractive candidates for disease triggers are environmental stimuli, such as cellular stressors that lead to protein-RNA granule formation. Several types of RNA granules, such as processing bodies (P bodies), stress granules, or RNP transporting granules offer a possible model for aggregate nucleation and thereby, disease initiation. Under physiological conditions, such protein-RNA complexes are formed transiently in a strictly regulated manner (Buchan and Parker, 2009; Wolozin, 2012) . However, under pathological conditions or due to chronic stress, these granules may act as precursors of the pathologic inclusions or pre-inclusions, which may transform into irreversible dense aggregates that can act as seeds of aggregation (Fig. 1B) . Indeed, TDP-43 (Bentmann et al., 2012; Fujita et al., 2008; Liu-Yesucevitz et al., 2010; McDonald et al., 2011; Udan-Johns et al., 2014) and FUS (Bentmann et al., 2012; Dormann et al., 2010) are incorporated in cytoplasmic and nuclear RNA granules. Stress granules and other RNA granules are likely to act as sites of nucleation, due to the increase of local TDP-43 and FUS concentration, which could facilitate the initiation of their aggregation. Moreover, the association with RNA in these granules may potentiate the ordered aggregation of TDP-43 and FUS. Such scaffolding capacity of RNA was established via the in vitro aggregation of the mammalian prion protein (Deleault et al., 2003) , as generation of infectious prions with purified cellular prion protein has been accomplished only by the addition of RNA and phospholipids (Wang et al., 2010) . We hypothesize that the RNAs naturally associated with TDP-43 and FUS might play a similar scaffolding role. It is also conceivable that depending on the type of associated RNA within the nucleating granules, various misfolded protein structures may arise, possibly resulting in different aggregate subtypes. Additionally, the pre-formed granules could play a toxic role by sequestering certain proteins and RNAs that are important for cell viability.
TDP-43 was also shown to transiently form intranuclear aggregates in response to heat shock (Udan-Johns et al., 2014) . This reaction was dependent on proteins from Hsp40/Hsp70 family, which interacted with the prion-like domain of TDP-43 and mediated protein aggregation. The latter was shown to result in altered interaction with other RNA-binding proteins, such as hnRNPA1, which indicates that stress conditions, and consequently aggregation, disrupt normal function of TDP-43 (Udan-Johns et al., 2014) .
Importantly, both TDP-43 (D'Amico et al., 2013; Fujita et al., 2008; Liu-Yesucevitz et al., 2010) and FUS (D'Amico et al., 2013; Dormann et al., 2010) were found in stress granules observed in ALS patients. Additionally, they colocalized with the stress granule marker TIA-1, another RNA-binding protein with a prion-like domain that drives stress granule formation and organization (Wolozin, 2012) . The cytoplasmic redistribution of TDP-43 (Colombrita et al., 2009; Dewey et al., 2011; Leggett et al., 2012; LiuYesucevitz et al., 2010; McDonald et al., 2011) and FUS (Andersson et al., 2008) and their association with stress granules could be recapitulated in cell culture by induction of various cell stresses, such as osmotic, oxidative or ER stress. Interestingly, these stress-induced aggregates turned into irreversible pathological inclusions, as they were shown to persist after removal of the stressor agent (Dewey et al., 2011; Dormann et al., 2010) . Furthermore, the association of TDP-43 (Bentmann et al., 2012; Dewey et al., 2011; Liu-Yesucevitz et al., 2010) and FUS (Bentmann et al., 2012) with stress granules depend on the presence of prion-like domain, as deletion of this region inhibited the process. Also, mutations within this domain resulted in enhanced stress granule formation kinetics and increased granule size (Dewey et al., 2011; Dormann et al., 2010; Ito et al., 2011; Liu-Yesucevitz et al., 2010) .
Another protein property shared by TDP-43 and FUS that potentially contributes to their self-perpetuating aggregation is the autoregulatory pathway that controls their levels. The pre-mRNAs encoding TDP-43 and FUS were identified among other targets bound by TDP-43 and FUS proteins (Lagier-Tourenne et al., 2012; . This binding leads to an autoregulation mechanism controlling their protein levels through binding of TDP-43 (Ayala et al., 2011; and FUS Zhou et al., 2013) to their own transcripts and regulating the RNA processing pathway. After an initiation phase, the formation of pre-inclusions containing misfolded TDP-43 or FUS would cause partial nuclear clearance, which in turn would lead to increased levels of stable TARDBP or FUS transcripts. Consequently, the levels of TDP-43 or FUS proteins would also rise providing high level of substrate protein for seeded aggregation, therefore contributing to growth of the pathogenic TDP-43 and FUS deposits. Taking into account that increased levels of TDP-43 mRNA were observed in motor neurons from ALS patients (Rabin et al., 2010) , such feed-forward mechanism could explain the aggregate propagation underlying ALS.
Non-cell autonomous toxicity
ALS is not only confined in the spinal cord and the brain stem, but it affects broadly the central nervous system (Geser et al., 2008 (Geser et al., , 2009 and is mediated by non-cell autonomous mechanisms (Boillee et al., 2006a; Ilieva et al., 2009 ). This means that besides motor neurons, other types of neurons or glial cells are also affected and contribute to ALS pathogenesis. Interestingly, glial cells were shown to mediate ALS pathology through the release or secretion of toxic factors (Boillee et al., 2006a; Yamanaka et al., 2008) . This non-cell autonomous mechanism was recapitulated in vitro, where mutant SOD1-expressing astrocytes were toxic to co-cultured motor neurons (Di Giorgio et al., 2007 . Importantly, this phenomenon was also observed for astrocytes derived from familial and sporadic ALS patients (Haidet-Phillips et al., 2011; Re et al., 2014) . Furthermore, gray matter oligodendrocytes in transgenic SOD1 mice presented pathogenic inclusions, prior to the manifestation of clinical symptoms (Kang et al., 2013) . In addition, a recently published study, reports on overlapping severity of TDP-43 pathology in neurons and oligodentrocytes, in different regions of the CNS in ALS patient samples. Interestingly, the gray matter oligodendroglia with TDP-43 inclusions, were also identified in areas devoid of affected neurons (Brettschneider et al., 2014) . These observations imply that the gray matter oligodendrocyte pathology may precede, and possibly trigger, pathology in neighboring neuronal cells in ALS (Brettschneider et al., 2014; Kang et al., 2013) . Lastly, microglial cells are also likely contributors in pathogenesis, as deletion of mutant SOD1 within microglia extended disease progression in mice (Boillee et al., 2006b ). In line with this, microglial pathology in ALS patient autopsy samples correlates with disease progression and is linked to severity of motor neuron loss (Brettschneider et al., 2012) .
Motor neurons are dependent on their neighboring glial cells, which are mainly responsible for neuronal metabolism support . Therefore, loss of physiological function of glial cells in early ALS pathogenic events, could enhance motor neuron damage, not only through secretion of toxic agents, but also by affecting neuron vulnerability and survival. Furthermore, the pathological changes in affected oligodendrocytes, which under normal conditions are responsible for formation of the myelin sheath, could explain the observed demyelination of neuronal axons in ALS patients.
Implication of prion-like spread for disease progression
The prion-like pathological protein propagation and neuroanatomic spread in ALS and other neurodegenerative diseases provide a molecular mechanism for disease progression . Indeed, in the recent years, many studies supporting such mechanisms for propagation and spread have been reported (Brettschneider et al., 2013 (Brettschneider et al., , 2014 Ravits, 2014; Ravits et al., 2007a Ravits et al., , 2007b Ravits and La Spada, 2009) .
Correlation of clinical symptoms and motor neuron loss in the neuraxis of ALS patients, showed focal and stochastic, location of disease initiation within the nervous system (Ravits, 2014; Ravits et al., 2007a Ravits et al., , 2007b Ravits and La Spada, 2009) . At the beginning of disease progression, the symptoms steadily worsen within the initial focally affected region. Over time, the pathology (Brettschneider et al., 2014) , and resulting motor impairment (Ravits et al., 2007a (Ravits et al., , 2007b start to spread through the nervous system. The propagation of pathological lesions most probably occurs contiguously, through side-to-side connections, between proximal regions (Ravits and La Spada, 2009 ). However, it is also conceivable that axonal transport and synaptic connections are involved in the dissemination of pathological inclusions across the nervous system (Brettschneider et al., 2013) . The severity of neuronal loss and motor dysfunction is maximal in the focal body area and gradually decreases outwards. Moreover, the site of initiation strongly determines the clinical manifestation of the disease (Ravits, 2014) . Together, with the observation that initial symptoms occur in random locations in different patients, these characteristics of ALS result in heterogeneous phenotypes, namely: (I) primary lateral sclerosis predominantly affecting upper motor neurons (UMNs); (II) primary muscular atrophy, characterized predominantly by degeneration of lower motor neurons (LMNs); (III) limb ALS characterized mostly by degeneration of motor neurons important for arm and leg function; and (IV) bulbar ALS, which affects neurons important for speech and swallowing (Ravits, 2014) .
In the most recent staging study, the distribution of neuronal loss and phosphorylated TDP-43 (pTDP-43), a hallmark of ALS pathology, was mapped within the central nervous system of ALS patients (Brettschneider et al., 2014) . It was shown that the most severe neuronal loss and aggregates containing pTDP-43 reside in the dorsolateral motor nuclei columns of the cervical and lumbosacral anterior horn. This suggests that these regions may be the earliest foci of TDP-43 pathology within the spinal cord. However, it remains unclear, if the spinal cord lesions comprise the initial TDP-43 nucleation sites or if they result from propagation of cortical TDP-43 pathological aggregates. Additionally, the molecular mechanisms of the release and uptake of seeds underlying the cell-to-cell spread also remain to be characterized.
Importantly, cell-to-cell propagation was observed in cultured cells transduced with TDP-43 and SOD1 (Grad and Cashman, 2014; Münch et al., 2011) aggregates. SOD1 transmission is possibly based on SOD1 uptake from neighboring cells through macropinocytosis (Grad and Cashman, 2014; Münch et al., 2011) upon protein release to extracellular space from dying cells, or through secretion of exosomes from living cells (Grad and Cashman, 2014) .
In conclusion, similarly to progression of prion diseases, motor neuron loss (Ravits et al., 2007a (Ravits et al., , 2007b and TDP-43 pathology (Brettschneider et al., 2014) start focally in specific sites and, during the progression of clinical disease, these pathological changes spread across specific CNS regions in a spatiotemporal manner. Future studies are needed to decipher the exact cellular and molecular mechanisms underlying the initiation and progression of ALS and the contribution of prion-like propagation to this process. Importantly, understanding this contribution is of outmost importance, since it would offer possibilities of therapeutic interventions by blocking protein aggregation and conversion, as well as with the transport of protein aggregates from cell to cell.
